{"id":"https://openalex.org/W2016386446","doi":"https://doi.org/10.1097/00001813-200511000-00009","title":"The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan","display_name":"The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan","publication_year":2005,"publication_date":"2005-10-12","ids":{"openalex":"https://openalex.org/W2016386446","doi":"https://doi.org/10.1097/00001813-200511000-00009","mag":"2016386446","pmid":"https://pubmed.ncbi.nlm.nih.gov/16222152"},"language":"en","primary_location":{"id":"doi:10.1097/00001813-200511000-00009","doi":"https://doi.org/10.1097/00001813-200511000-00009","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-200511000-00009","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111661412","display_name":"Ada Braun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ada Henrike Braun","raw_affiliation_strings":["Department of Internal Medicine (Cancer Research), West German Cancer Center, Essen, Germany. ada.h.braun@vanderbilt.edu","Department of Internal Medicine (Cancer Research), West German Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center, Essen, Germany. ada.h.braun@vanderbilt.edu","institution_ids":[]},{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Katrin Stark","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katrin Stark","raw_affiliation_strings":["Department of Internal Medicine (Cancer Research), West German Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086901007","display_name":"Olaf Dirsch","orcid":"https://orcid.org/0000-0003-2791-2061","observed_orcids":["https://orcid.org/0000-0003-2791-2061"]},"institutions":[{"id":"https://openalex.org/I62318514","display_name":"University of Duisburg-Essen","ror":"https://ror.org/04mz5ra38","country_code":"DE","type":"education","lineage":["https://openalex.org/I62318514"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Olaf Dirsch","raw_affiliation_strings":["Institute of Pathology, University of Duisberg-Essen Medical School, Essen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pathology, University of Duisberg-Essen Medical School, Essen, Germany","institution_ids":["https://openalex.org/I62318514"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112066590","display_name":"Ralf Axel Hilger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ralf Axel Hilger","raw_affiliation_strings":["Department of Internal Medicine (Cancer Research), West German Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111640624","display_name":"S. Seeber","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Siegfried Seeber","raw_affiliation_strings":["Department of Internal Medicine (Cancer Research), West German Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110482131","display_name":"Udo J. Vanhoefer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Udo Vanhoefer","raw_affiliation_strings":["Department of Internal Medicine (Cancer Research), West German Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine (Cancer Research), West German Cancer Center","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5111661412"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.1333,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.86144407,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"16","issue":"10","first_page":"1099","last_page":"1108"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9710000157356262},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.8920000195503235},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8270000219345093},{"id":"https://openalex.org/keywords/sn-38","display_name":"SN-38","score":0.8180000185966492},{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.824999988079071},{"id":"https://openalex.org/keywords/topoisomerase-i","display_name":"topoisomerase I","score":0.9359999895095825},{"id":"https://openalex.org/keywords/single-strand-breaks","display_name":"single-strand breaks","score":0.9340000152587891},{"id":"https://openalex.org/keywords/g1-cell-cycle-arrest","display_name":"G1 cell cycle arrest","score":0.8539999723434448},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.550000011920929},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.49799999594688416},{"id":"https://openalex.org/keywords/protein-kinase-c","display_name":"protein kinase C","score":0.7319999933242798},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7699999809265137}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9289597272872925},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6986788511276245},{"id":"https://openalex.org/C2780508388","wikidata":"https://www.wikidata.org/wiki/Q1750127","display_name":"SN-38","level":5,"score":0.5927588939666748},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.55623859167099},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5503824353218079},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.5310191512107849},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4992067813873291},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.48346978425979614},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.43255817890167236},{"id":"https://openalex.org/C97029542","wikidata":"https://www.wikidata.org/wiki/Q281417","display_name":"Protein kinase A","level":3,"score":0.420940101146698},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.4061616063117981},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.40526852011680603},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4003516137599945},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3739423453807831},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36952346563339233},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30546802282333374},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2835705578327179},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25670570135116577},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15588980913162231},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000951","descriptor_name":"Antigens, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D000951","descriptor_name":"Antigens, Neoplasm","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004250","descriptor_name":"DNA Topoisomerases, Type II","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D004250","descriptor_name":"DNA Topoisomerases, Type II","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004268","descriptor_name":"DNA-Binding Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D004268","descriptor_name":"DNA-Binding Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015536","descriptor_name":"Down-Regulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019927","descriptor_name":"Cyclin E","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00001813-200511000-00009","doi":"https://doi.org/10.1097/00001813-200511000-00009","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-200511000-00009","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:16222152","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16222152","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W165178680","https://openalex.org/W201144216","https://openalex.org/W1523413020","https://openalex.org/W1549846058","https://openalex.org/W1588983486","https://openalex.org/W1595184397","https://openalex.org/W1632388334","https://openalex.org/W1838547618","https://openalex.org/W1984246155","https://openalex.org/W2005525303","https://openalex.org/W2019327140","https://openalex.org/W2020963512","https://openalex.org/W2027230571","https://openalex.org/W2030796899","https://openalex.org/W2039140611","https://openalex.org/W2042367294","https://openalex.org/W2046264538","https://openalex.org/W2054614254","https://openalex.org/W2057409012","https://openalex.org/W2061510201","https://openalex.org/W2064326390","https://openalex.org/W2068744776","https://openalex.org/W2109689528","https://openalex.org/W2112055293","https://openalex.org/W2118553080","https://openalex.org/W2119687650","https://openalex.org/W2122872787","https://openalex.org/W2126314379","https://openalex.org/W2127843578","https://openalex.org/W2128088579","https://openalex.org/W2146380722","https://openalex.org/W2164062990","https://openalex.org/W2168377135","https://openalex.org/W2317936438","https://openalex.org/W2329407609","https://openalex.org/W2409509945","https://openalex.org/W2418265888","https://openalex.org/W4256405054"],"related_works":["https://openalex.org/W2064326390","https://openalex.org/W2071368017","https://openalex.org/W1974662122","https://openalex.org/W2027192632","https://openalex.org/W2378588995","https://openalex.org/W2018373178","https://openalex.org/W2122185071","https://openalex.org/W2156609950","https://openalex.org/W2062679793","https://openalex.org/W2104135961"],"abstract_inverted_index":{"Epidermal":[0],"growth":[1],"factor":[2],"receptor":[3],"(EGFR)":[4],"overactivity":[5],"plays":[6],"a":[7,84,128,160],"significant":[8,109,175],"role":[9],"in":[10,53,83,153,177],"colon":[11,55,63],"cancer":[12,56,64],"biology":[13],"and":[14,111,118,203],"has":[15],"been":[16],"associated":[17],"with":[18,87],"poor":[19],"clinical":[20,23,33],"prognosis.":[21],"Early":[22],"trials":[24],"reported":[25],"efficacy":[26],"of":[27,32,40,50,71,78,90,114,120,163,181],"receptor-targeted":[28],"compounds,":[29],"including":[30,140],"modulation":[31],"irinotecan":[34,51,202],"resistance.":[35],"We":[36],"investigated":[37],"the":[38,41,68,75,164,182,198],"effects":[39],"EGFR":[42,204],"tyrosine":[43],"kinase":[44,143,146],"inhibitor":[45],"gefitinib":[46,61],"on":[47],"cellular":[48,171],"determinants":[49],"resistance":[52],"human":[54],"cells.":[57],"At":[58],"non-cytotoxic":[59],"concentrations,":[60],"sensitized":[62],"cells":[65],"to":[66,127,197],"SN-38,":[67],"active":[69,183],"metabolite":[70],"irinotecan.":[72],"Gefitinib":[73,134],"increased":[74],"SN-38-mediated":[76],"induction":[77],"protein-linked":[79],"DNA":[80],"single-strand":[81],"breaks":[82],"dose-dependent":[85,161],"manner,":[86],"no":[88,174],"alteration":[89],"topoisomerase":[91,156],"(Topo)":[92],"I":[93],"protein":[94,102,117,142,145],"expression":[95,103],"or":[96,144,155,179],"enzymatic":[97,122],"activity.":[98],"Whereas":[99],"Topo":[100,115],"IIbeta":[101],"was":[104,167],"not":[105],"affected":[106],"by":[107],"gefitinib,":[108,170],"time-":[110],"concentration-dependent":[112],"downregulation":[113],"IIalpha":[116],"inhibition":[119],"its":[121],"function":[123],"were":[124],"observed,":[125],"corresponding":[126],"G1":[129],"phase":[130],"cell":[131],"cycle":[132],"arrest.":[133],"significantly":[135],"inhibited":[136],"EGFR-associated":[137],"signaling":[138],"molecules,":[139],"phospho-mitogen-activated":[141],"C,":[147],"which":[148],"may":[149,195],"account":[150],"for":[151],"decreases":[152],"proliferation":[154],"activity,":[157],"respectively.":[158],"Although":[159],"decrease":[162],"BCRP/MXR/ABCP":[165],"half-transporter":[166],"observed":[168,200],"under":[169],"pharmacokinetics":[172],"revealed":[173],"differences":[176],"accumulation":[178],"retention":[180],"SN-38":[184],"lactone":[185],"using":[186],"reverse-phase":[187],"HPLC":[188],"analysis.":[189],"This":[190],"study":[191],"delineates":[192],"mechanisms":[193],"that":[194],"contribute":[196],"synergism":[199],"between":[201],"inhibitors.":[205]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}